Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label eptinezumab study in chronic cluster headache
NL-OMON54055Phase 3Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of eptinezumab in Cluster Headache (CH), sponsored by Lundbeck. Primary endpoints: Adverse events, Clinical safety laboratory values and 4 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
eptinezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON54055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54055.